Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?

A. Laparra; M. Kfoury; S. Champiat; F. X. Danlos; P. Martin-Romano; A. Simonaggio; C. Baldini; P. Vuagnat; C. Mateus; A. L. Voisin; L. Albiges; B. Besse; C. Even; C. Robert; S. Laghouati; C. Massard; A. Marabelle; O. Lambotte; J. M. Michot

doi:10.1016/j.annonc.2021.04.006

Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?

A. Laparra, M. Kfoury, S. Champiat, F. X. Danlos, P. Martin-Romano, A. Simonaggio, C. Baldini, P. Vuagnat, C. Mateus, A. L. Voisin, L. Albiges, B. Besse, C. Even, C. Robert, S. Laghouati, C. Massard, A. Marabelle, O. Lambotte, J. M. Michot

Research output: Contribution to journal › Letter › peer-review

4 Citations (Scopus)

Original language	English
Pages (from-to)	936-937
Number of pages	2
Journal	Annals of Oncology
Volume	32
Issue number	7
DOIs	https://doi.org/10.1016/j.annonc.2021.04.006
Publication status	Published - 1 Jul 2021

Access to Document

10.1016/j.annonc.2021.04.006

Cite this

Laparra, A., Kfoury, M., Champiat, S., Danlos, F. X., Martin-Romano, P., Simonaggio, A., Baldini, C., Vuagnat, P., Mateus, C., Voisin, A. L., Albiges, L., Besse, B., Even, C., Robert, C., Laghouati, S., Massard, C., Marabelle, A., Lambotte, O., & Michot, J. M. (2021). Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials? Annals of Oncology, 32(7), 936-937. https://doi.org/10.1016/j.annonc.2021.04.006

@article{854d5fbb08fc419a931450ec7f8ac426,

title = "Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?",

author = "A. Laparra and M. Kfoury and S. Champiat and Danlos, {F. X.} and P. Martin-Romano and A. Simonaggio and C. Baldini and P. Vuagnat and C. Mateus and Voisin, {A. L.} and L. Albiges and B. Besse and C. Even and C. Robert and S. Laghouati and C. Massard and A. Marabelle and O. Lambotte and Michot, {J. M.}",

note = "Funding Information: None declared. JMM is a principal/sub-investigator of clinical trials for Abbvie, Agios, Amgen, Astex, AstraZeneca, BMS, Boeringer Ingelheim, Celgene, Debiopharm, Forma, Genentech, GSK, Incyte, Innate Pharma, Janssen, Lilly, Loxo, Medimmune, MSD, Novartis, Pfizer, Pharmamar, Roche, Sanofi and Xencor; and reports non-financial support (drugs, equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.) from AstraZeneca, Roche, Novartis, Gilead, Celgene and Bristol-Myers Squibb. OL reports paid expert testimony and consultancy fees from BMS France, MSD and AstraZeneca; consultancy fees from Incyte; and expert testimony for Janssen. CM is a principal/sub-investigator of clinical trials for Abbvie, Agios, Amgen, Astex, AstraZeneca, BMS, Boeringer Ingelheim, Celgene, Debiopharm, Forma, Genentech, GSK, Incyte, Innate Pharma, Janssen, Lilly, Loxo, Medimmune, MSD, Novartis, Pfizer, Pharmamar, Roche, Sanofi and Xencor. AM is a principal/sub-investigator of clinical trials for Abbvie, Agios, Amgen, Astex, AstraZeneca, BMS, Boeringer Ingelheim, Celgene, Debiopharm, Forma, Genentech, GSK, Incyte, Innate Pharma, Janssen, Lilly, Loxo, Medimmune, MSD, Novartis, Pfizer, Pharmamar, Roche, Sanofi and Xencor. All other authors have declared no conflicts of interest.",

year = "2021",

month = jul,

day = "1",

doi = "10.1016/j.annonc.2021.04.006",

language = "English",

volume = "32",

pages = "936--937",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "7",

}

Laparra, A, Kfoury, M, Champiat, S, Danlos, FX, Martin-Romano, P, Simonaggio, A, Baldini, C, Vuagnat, P, Mateus, C, Voisin, AL, Albiges, L, Besse, B, Even, C, Robert, C, Laghouati, S, Massard, C, Marabelle, A, Lambotte, O & Michot, JM 2021, 'Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?', Annals of Oncology, vol. 32, no. 7, pp. 936-937. https://doi.org/10.1016/j.annonc.2021.04.006

TY - JOUR

T1 - Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies

T2 - a new surrogate marker for clinical trials?

AU - Laparra, A.

AU - Kfoury, M.

AU - Champiat, S.

AU - Danlos, F. X.

AU - Martin-Romano, P.

AU - Simonaggio, A.

AU - Baldini, C.

AU - Vuagnat, P.

AU - Mateus, C.

AU - Voisin, A. L.

AU - Albiges, L.

AU - Besse, B.

AU - Even, C.

AU - Robert, C.

AU - Laghouati, S.

AU - Massard, C.

AU - Marabelle, A.

AU - Lambotte, O.

AU - Michot, J. M.

N1 - Funding Information: None declared. JMM is a principal/sub-investigator of clinical trials for Abbvie, Agios, Amgen, Astex, AstraZeneca, BMS, Boeringer Ingelheim, Celgene, Debiopharm, Forma, Genentech, GSK, Incyte, Innate Pharma, Janssen, Lilly, Loxo, Medimmune, MSD, Novartis, Pfizer, Pharmamar, Roche, Sanofi and Xencor; and reports non-financial support (drugs, equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.) from AstraZeneca, Roche, Novartis, Gilead, Celgene and Bristol-Myers Squibb. OL reports paid expert testimony and consultancy fees from BMS France, MSD and AstraZeneca; consultancy fees from Incyte; and expert testimony for Janssen. CM is a principal/sub-investigator of clinical trials for Abbvie, Agios, Amgen, Astex, AstraZeneca, BMS, Boeringer Ingelheim, Celgene, Debiopharm, Forma, Genentech, GSK, Incyte, Innate Pharma, Janssen, Lilly, Loxo, Medimmune, MSD, Novartis, Pfizer, Pharmamar, Roche, Sanofi and Xencor. AM is a principal/sub-investigator of clinical trials for Abbvie, Agios, Amgen, Astex, AstraZeneca, BMS, Boeringer Ingelheim, Celgene, Debiopharm, Forma, Genentech, GSK, Incyte, Innate Pharma, Janssen, Lilly, Loxo, Medimmune, MSD, Novartis, Pfizer, Pharmamar, Roche, Sanofi and Xencor. All other authors have declared no conflicts of interest.

PY - 2021/7/1

Y1 - 2021/7/1

UR - http://www.scopus.com/inward/record.url?scp=85107902413&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.04.006

DO - 10.1016/j.annonc.2021.04.006

M3 - Letter

C2 - 33865965

AN - SCOPUS:85107902413

SN - 0923-7534

VL - 32

SP - 936

EP - 937

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

ER -

Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?

Access to Document

Other files and links

Cite this